Abstract
Metabolic reprogramming is a well-described hallmark of clear-cell renal cell carcinoma (ccRCC). Gene copy-number variation and altered gene expression data suggest that enhanced branched-chain amino acid (BCAA) transamination and reduced BCAA oxidation are highly selected traits in ccRCC. Surprisingly, we found that genetic modulation of BCAA oxidation had little effect on experimental ccRCC cell growth in vitro and in vivo. In contrast, BCAA transamination in ccRCC cells was essential for the generation of glutamate (GLU)-derived glutathione (GSH) and cell viability when glutamine was limiting. Thus, BCAA transamination conferred resistance to states of low glutamine or treatment with the glutaminase (GLS) inhibitor CB-839 by providing GSH independent of glutamine breakdown. Targeting BCAA transamination in vitro and in vivo sensitized ccRCC to CB-839–mediated GLS inhibition by decreasing GSH biosynthesis and redox homeostasis. These findings reveal that BCAA transamination maintains critical GLU and GSH levels in glutamine-deprived ccRCC, explaining why CB-839 treatment has been ineffective in ccRCC clinical trials, and demonstrate an approach to treat ccRCC by targeting BCAA transamination to create a vulnerability to GLS inhibition. Significance: Branched-chain amino acid transamination maintains essential glutamate and glutathione levels in glutamine-deprived clear cell renal cell carcinoma and can be targeted to sensitize tumors to glutaminase inhibition by impairing redox homeostasis.
Funding Information
  • National Cancer Institute (R35 CA220483)
  • National Cancer Institute (P30 CA016520)
  • National Cancer Institute (F30 CA271654)
  • National Cancer Institute (T32 CA009592)
  • American Cancer Society (PF-23-1034739-01-TBE)
  • Damon Runyon Cancer Research Foundation (DRG2497)
  • Ludwig Institute for Cancer Research
  • U.S. Department of War (KC220099)